KB LAMINATES
01888
CHINA CINDA
01359
CHINAHONGQIAO
01378
DONGFENG GROUP
00489
U-PRESID CHINA
00220
HK Stock MarketDetailed Quotes
06826 HAOHAI BIOTEC
- 26.900
- -0.100-0.37%
Market Closed Dec 27 16:08 CST
6.30BMarket Cap13.21P/E (TTM)
27.000High26.600Low192.42KVolume26.600Open27.000Pre Close5.15MTurnover0.48%Turnover Ratio13.72P/E (Static)234.19MShares42.95052wk High1.00P/B1.08BFloat Cap20.49152wk Low1.23Dividend TTM40.14MShs Float104.587Historical High0.791Dividend LFY1.48%Amplitude13.033Historical Low26.777Avg Price100Lot Size4.58%Div YieldTTM2.94%Div Yield LFY
HAOHAI BIOTEC News
HAOHAI BIOTEC (06826.HK) spent 1.948 million yuan to repurchase 0.0315 million A shares on December 27.
Gelonghui, December 27th丨HAOHAI BIOTEC (06826.HK) announced that on December 27, 2024, it spent 1.948 million yuan to repurchase 0.0315 million A-shares at a repurchase price of 61.62-62 yuan per share.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
HAOHAI BIOTEC (06826.HK) spent 0.2913 million HKD to repurchase 0.011 million shares on December 23.
Gelonghui reported on December 23 that HAOHAI BIOTEC (06826.HK) announced that on December 23, 2024, it spent 0.2913 million Hong Kong dollars to repurchase 0.011 million shares, with a repurchase price of 26.45-26.5 Hong Kong dollars per share.
Recent 6.3% Pullback Would Hurt Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Insiders
HAOHAI BIOTEC (06826.HK) spent 1.0705 million HKD to repurchase 0.04 million shares on December 20.
Gelonghui reported on December 20 that HAOHAI BIOTEC (06826.HK) announced it spent HKD 1.0705 million to repurchase 0.04 million shares, with a repurchase price of HKD 26.7-26.85 per share. On the same day, the company spent RMB 1.9862 million to repurchase 0.032 million shares, with a repurchase price of RMB 61.94-62.2 per share.
HAOHAI BIOTEC (06826.HK) spent 1.048 million Hong Kong dollars to repurchase 0.039 million shares on December 19.
Gelonghui reported on December 19 that HAOHAI BIOTEC (06826.HK) announced that on December 19, it spent 1.048 million Hong Kong dollars to repurchase 0.039 million shares, with a repurchase price of 26.75-27 Hong Kong dollars per share.
HAOHAI BIOTEC (06826.HK) spent 0.282 million Hong Kong dollars to repurchase 0.0104 million shares on December 18.
On December 18, Gelonghui reported that HAOHAI BIOTEC (06826.HK) announced that on December 18, it spent 0.282 million Hong Kong dollars to repurchase 0.0104 million shares.
HAOHAI BIOTEC (06826.HK) spent 0.766 million HKD to repurchase 0.028 million shares on December 17.
Gelonghui, December 17: HAOHAI BIOTEC (06826.HK) announced that it spent 0.766 million Hong Kong dollars on December 17 to repurchase 0.028 million shares.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
On December 5, haohai biotec (06826) spent 0.8066 million Hong Kong dollars to repurchase 0.0295 million shares.
haohai biotec (06826) announced that the company invested 0.8066 million Hong Kong dollars on December 5, 2024...
Haohai Biotec (06826.HK) spent 0.199 million HKD to repurchase 7,200 shares on December 4.
On December 4, haohai biotec (06826.HK) announced that it spent 0.199 million Hong Kong dollars to repurchase 7200 shares on December 4.
haohai biotec (06826.HK) spent 0.363 million Hong Kong dollars to repurchase 0.013 million shares on December 3.
Grain Meeting December 3rd | haohai biotec (06826.HK) announced that on December 3, 2024, it spent 0.363 million Hong Kong dollars to repurchase 0.013 million shares at a repurchase price of HK$27.85-28 per share.
haohai biotec (06826.HK) has repurchased a total of 0.138 million shares of A-shares as of November 30, 2024.
Gelonghui, December 2nd丨haohai biotec (06826.HK) announced that as of November 30, 2024, the company has repurchased a total of 138,150 A-shares through centralized bidding trade, accounting for 0.06% of the company's total share capital of 234,190,295 shares. The highest fill price was 63.58 yuan per share, the lowest fill price was 62.73 yuan per share, and the total transaction amount was 8,725,748.33 yuan (excluding stamp duty, transaction commission, and other transaction costs).
Haohai Biotec (06826.HK) spent 0.2071 million Hong Kong dollars to repurchase 7500 shares on December 2nd.
On December 2, Gelonghui reported that haohai biotec (06826.HK) announced the repurchase of 7,500 shares at a cost of 0.2071 million Hong Kong dollars on December 2, 2024, with a repurchase price of 27.6-27.65 Hong Kong dollars per share.
Haohai Biotec (06826) plans to use no more than 0.4 billion yuan of temporarily idle raised funds for cash management.
Haohai Biotec (06826) announced that the company plans to use no more than 0.4 billion yuan (including this amount) of temporarily idle...
Shanghai Haohai Biological Technology (688366.SH): plans to use no more than 0.4 billion yuan of temporarily idle raised funds for cash management.
On November 29, Gelonghui reported that shanghai haohai biological technology (688366.SH) announced that the company plans to use temporarily idle raised funds for cash management, with a maximum amount not exceeding 400 million yuan, provided that it does not affect the normal progress of the company's fundraising investment plan. The funds will be used to purchase high-security, good liquidity, and guaranteed principal investment products (including but not limited to agreed deposits, notice deposits, term deposits, large certificates of deposit, income certificates, etc.), with a duration not exceeding the construction period of the fundraising projects and valid within 12 months from the date of approval by the board of directors. Within the aforementioned limit and timeframe, the company can recycle.
Shanghai Haohai Biological Technology (688366.SH): Shareholders Lou Guoliang collectively reduce their shareholding by no more than 0.8 million shares in the company.
On November 29, Gelonghui reported that Shanghai Haohai Biological Technology (688366.SH) announced that shareholder Mr. Lou Guoliang plans to reduce his shareholding by no more than 800,000 shares within three months starting from three trading days after this announcement, due to his own funding needs. This represents no more than 0.3416% of the company's total share capital of 234,190,295 shares, with the reduction of no more than 800,000 shares through centralized bidding and no more than 800,000 shares through block trading. The reduction price will be determined based on the secondary market price.
Haohai Biotec (06826) spent 0.5067 million Hong Kong dollars to repurchase 0.018 million shares on November 29.
haohai biotec (06826) announced that on November 29, 2024, the company invested 0.5067 million...
Haohai Biotec (06826) repurchased 0.01 million shares on November 28 for 0.2764 million HKD.
haohai biotec (06826) announced that on November 28, 2024, the company invested 27.64...
Trending HK Stocks
HK Dividend Stocks HK Dividend Stocks
Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data. Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data.
